Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies

被引：5
|
作者：
Rosell, R.
Molina, M. A.
Costa, C.
Taron, M.
Bertran-Alamillo, J.
Mayo, C.
Benlloch, S.
Moran, T.
Cardenal, F.
Porta, R.
机构：
[1] Catalan Inst Oncol, Badalona, Spain
[2] USP Inst Univ Dexeus, Pangaea Biotech, Barcelona, Spain
[3] USP Dexeus Univ Inst, Pangaea Biotech, Barcelona, Spain
[4] USP Inst Dexeus, Pangaea Biotech, Barcelona, Spain
[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain
[6] Bellvitge Hosp, Catalan Inst Oncol, Barcelona, Spain
[7] Hosp Josep Trueta, Catalan Inst Oncol, Girona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7514
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PRETREATMENT EGFR T790M MUTATION AND BRCA1 MRNA EXPRESSION IN ERLOTINIB-TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH EGFR MUTATIONS
    Rosell, R.
    Molina, M. A.
    Costa, C.
    Bertran-Alamillo, J.
    Mayo, C.
    Moran, T.
    Viteri, S.
    Mendez, P.
    Benlloch, S.
    Taron, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 129 - 129
  • [2] Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
    Rosell, Rafael
    Angel Molina, Miguel
    Costa, Carlota
    Simonetti, Sara
    Gimenez-Capitan, Ana
    Bertran-Alamillo, Jordi
    Mayo, Clara
    Moran, Teresa
    Mendez, Pedro
    Cardenal, Felipe
    Isla, Dolores
    Provencio, Mariano
    Cobo, Manuel
    Insa, Amelia
    Garcia-Campelo, Rosario
    Reguart, Noemi
    Majem, Margarita
    Viteri, Santiago
    Carcereny, Enric
    Porta, Ruth
    Massuti, Bartomeu
    Queralt, Cristina
    de Aguirre, Itziar
    Miguel Sanchez, Jose
    Sanchez-Ronco, Maria
    Luis Mate, Jose
    Ariza, Aurelio
    Benlloch, Susana
    Javier Sanchez, Jose
    Bivona, Trever G.
    Sawyers, Charles L.
    Taron, Miquel
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (05) : 1160 - 1168
  • [3] De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy
    Rosell, Rafael
    Angel Molina, Miguel
    Javier Sanchez, Jose
    Taron, Miguel
    Benlloch, Susana
    Moran, Teresa
    Carcereny, Enric
    Cardenal, Felipe
    Massuti, Bartomeu
    Magri, Ignacio
    [J]. CANCER RESEARCH, 2011, 71
  • [4] Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
    Kuang, Yanan
    Rogers, Andrew
    Yeap, Beow Y.
    Wang, Lilin
    Makrigiorgos, Mike
    Vetrand, Kristi
    Thiede, Sara
    Distel, Robert J.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (08) : 2630 - 2636
  • [5] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [6] The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E plus B) in the BELIEF trial
    Rosell, Rafael
    Karachaliou, Niki
    Gimenez-Capitan, Ana
    Codony-Servat, Caries
    Gautschi, Oliver
    Felip, Enriqueta
    Curioni-Fontecedro, Alessandra
    Peters, Solange
    Ponce-Aix, Santiago
    Fruh, Martin
    Pless, Miklos
    Popat, Sanjay
    Cuffe, Sinead
    Bidoli, Paolo
    Favaretto, Adolfo
    Kamnnler, Roswitha
    Dafni, Urania
    Tsourti, Zoi
    Molina-Vila, Miguel Angel
    Stahel, Rolf A.
    [J]. CANCER RESEARCH, 2016, 76
  • [7] Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
    Sakai, Asao
    Kasahara, Kazuo
    Sone, Takashi
    [J]. CASE REPORTS IN ONCOLOGY, 2013, 6 (01): : 15 - 20
  • [8] ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target
    Karachaliou, Niki
    Drozdowskyj, Ana
    Costa, Carlota
    Angel Molina-Vila, Miguel
    Gimenez Capitan, Ana
    Vergnenegre, Alain
    Massuti, Bartomeu
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Carcereny Costa, Enric
    Rosario Garcia-Campelo, M.
    Viteri Ramirez, Santiago
    Nicole Heidecke, Cordula
    Estrada-Tejedor, Roger
    Teixido, Jordi
    Grant Bivona, Trever
    Giannikopoulos, Petros
    Ono, Mayumi
    Rosell, Rafael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
    Yoshiya Matsumoto
    Tomoya Kawaguchi
    Masaru Watanabe
    Shun-ichi Isa
    Masahiko Ando
    Akihiro Tamiya
    Akihito Kubo
    Chiyoe Kitagawa
    Naoki Yoshimoto
    Yasuhiro Koh
    [J]. BMC Cancer, 22
  • [10] Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
    Matsumoto, Yoshiya
    Kawaguchi, Tomoya
    Watanabe, Masaru
    Isa, Shun-ichi
    Ando, Masahiko
    Tamiya, Akihiro
    Kubo, Akihito
    Kitagawa, Chiyoe
    Yoshimoto, Naoki
    Koh, Yasuhiro
    [J]. BMC CANCER, 2022, 22 (01)
12345